Moreover, the correlation between FXYD5 mRNA expression and clinical features revealed that the FXYD5 mean expression value was significantly higher in HGSOC patients showing platinum resistance compared to platinum sensitivity (FC = 2.45, 95% CI 1.52–3.97, p < 0.001), as well as in patients that experienced relapse or cancer progression compared to the others (FC = 2.01, 95% CI 1.03–3.94, p = 0.042) (Table 2). The gene discussed is FXYD5; the disease is cancer.